CHANGES OF SERUM CYTOKINE AND IRON HOMEOSTASIS INDICES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CHRONIC PYELONEPHRITIS: COMPLEX TREATMENT DYNAMICS
DOI:
https://doi.org/10.11603/1811-2471.2018.v0.i1.8590Keywords:
chronic obstructive pulmonary disease, pyelonephritis, interleukins, urolithiasis, magnesium.Abstract
Introduction. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), complex therapy for COPD and comorbid pathologies, especially of the renal system, such as chronic pyelonephritis (CP), urolithiasis (UL) provides better control of exacerbations and prevents complications. In this case chronic inflammation provokes an increase in the levels of interleukins -1β, 6 (IL-1β, 6) that affects the levels of transport forms of iron - ferritin, transferrin causing sideropenic syndrome. Pathogenetic features of comorbid COPD and CP have not been studied enough and require detailed examination in order to improve treatment outcomes.
The aim of the study – to determine changes of cytokine profile and iron transport in patients with COPD, CP and UL comorbidity in dynamics of complex treatment with magnesium and pyridoxine supplement.
Material and Methods. 37 patients with chronic obstructive pulmonary disease, chronic pyelonephritis and urolithiasis of different severity were involved. Patients were divided into 2 groups depending on the treatment. In addition to standard treatment, the main study group received therapy with magnesium lactate dihydrate 470 mg and pyridoxine hydrochloride 5 mg. A comparative analysis of interleukins-1β and 6, iron transport forms levels before and after treatment was performed.
Results. Studies of the cytokine and iron metabolism profile in patients with comorbid COPD, CP, and UL who alongside with standard treatment got magnesium lactate dihydrate and pyridoxine hydrochloride supplement showed an increased level of serum iron 1.6 times more (p<0.05) in comparison to results before the treatment and decreased levels of IL-1β,6 2,0 times less (p<0.05). Improvement of patients' health state, positive change in clinical signs of comorbid COPD and CP signify a renewal of iron formation and transport.
Conclusions. Completion of standard therapy with magnesium and pyridoxine supplement helps to normalize cytokine levels, levels of serum iron, ferritin and clinical course, so it is advisable to use magnesium and pyridoxine supplementation in such patients.
References
Palange, P. (1998). Renal and hormonal abnormalities in chronic obstructive pulmonary disease (COPD). Thorax, 53, 989-991.
Feshchenko, Yu.I., Yashyna, L.O., & Potochniak, O.V. (2013). Khronichne obstruktyvne zakhvoriuvannia lehen ta suputnia depresiia – vazhlyva medyko-sotsialna problema [Chronic obstructive pulmonary disease and concomitant depression are an important medical and social problem]. Ukrainskyi pulmonolohichnyi zhurnal – Ukrainian Pulmono logy Journal, 3, 56-58 [in Ukrainian].
Zhyhunova, A.K. (2014). Kompleksnaya terapiya pri dismetabolicheskoy nefropatii razlichnogo geneza. Rol fitoterapii [Complex treatment of dysmetabolic nephropa- thy of different genesis. The role of phytotherapy]. Liky Ukrainy – Drugs of Ukraine, 78 (183-184),12-22 [in Russian].
Skolarikos, A. (2015). Metabolic evaluation and re- currence prevention for urinary stone patients: EAU Guidelines. European Urology, 67 (4), 750-763.
Franceschi, С., & Campisi, J. (2014). Chronic inflam- mation (inflammaging) and its potential contribution to age-associated diseases. Advances in geroscience: Impact on healthspan and chronic disease perspective, 69, 4-6.
Mydlík, M., Derzsiová, K., & Žemberová, E. (1997). Metabolism of vitamin B6 and its requirement in chronic renal failure. Kidney Int., 52, 62, 56–59.
From the Global Strategy for the Diagnosis, Mana- gement and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2017. [Internet]; [cited 17 of June 2017]. Available from: http://gold- copd.org.
Khukhlina, O.S., Vilihorska, V. (2013). Stan systemy krovotvorennia u khvorykh na khronichne obstruktyvne zakhvoriuvannia lehen ta sechokamianu khvorobu [The state of the erythropoietic system in patients with chronic obstructive pulmonary disease and urolithiasis]. Materialy naukovopraktychnoi konferentsii “Komorbidnist u klinitsi vnutrishnoi medytsyny: faktory ryzyku, mekhanizmy rozvytku ta vzaiemoobtiazhennia, osoblyvosti farmakoterapii” – Materials of the scientific and practical conference "Comorbidity in the clinic of internal medicine: risk factors, mecha- nisms of development and mutual burden, features of pharmacotherapy". Chernivtsi: BDMU [in Ukrainian].
Tsantikos, E., Maxwell, M.J., Putoczki, T., Ernst, M., Rose-John, S., & Tarlinton, D.M. (2013). Interleukin-6 trans- signaling exacerbates inflammation and renal pathology in lupus-prone mice. Arthritis & Rheumatism, 65, 2691- 2702. doi:10.1002/art.38061
Monico, C.G., Rossetti, S., Olson, J.B. (2005). Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney International, 67 (5), 1704-1709, ISSN 0085-2538, http://dx.doi. org/10.1111/j.1523-1755.2005.00267.x.
Van Itallie, C.M., & Anderson, J.M. (2006). Claudins and epithelial paracellular transport. Annu. Rev. Physiol., 68, 403-429.
Rosner, B. (2003). Fundamentals of biostatistics, 6 th ed. Belmont: Duxbury Press.
